Functional tissue regeneration remains an elusive goal for the treatment of a variety of traumatic injuries and chronic degenerative diseases that afflict a significant portion of the general population. Although mammals successfully regenerate tissues during early stages of fetal development, this trait is irreversibly lost as mammals mature. The contrast between embryonic and adult wound healing mechanisms suggests that the microenvironment that facilitates proper tissue regeneration in embryos is distinctly different from that of adult somatic tissues. Therefore, obtaining and introducing the molecular constituents of embryonic microenvironments to sites of adult tissue injury or disease may alter the course of endogenous tissue repair, yielding functional neo-tissues. A number of stem cell therapies are being developed in an attempt to restore the cellularity of damaged tissues, and in most instances, despite low levels of engraftment and differentiation into mature cell types, transplanted stem cells evoke significant functional improvements in the regenerative potential of tissues, indicating that the factors produced by stem cells may in fact directly impact tissue morphogenesis. This concept suggests a potential paradigm shift in the development and application of regenerative stem cell therapies - from cell replacement substitutes to biocatalytic agents of tissue regeneration. Thus, the objective of this proposal is to develop engineered biomaterials capable of sequestering morphogenic factors produced by differentiating embryonic stem cells (ESCs) and to deliver ESC-derived morphogens to adult wound sites in order to enhance tissue regeneration. These studies will provide new insights into the regenerative function of pluripotent stem cells and mechanisms of mammalian tissue repair, as well as directly lead to the development of a new class of regenerative molecular therapeutics to treat a variety of traumatic injuries and degenerative diseases.
The inability of adult mammals to restore normal tissue structure and function following traumatic injury or due to degenerative disease remains a leading challenge to the development of effective biomedical therapies. Stem cells are capable of differentiating into cell types that could be used to replace cells lost due to injury and disease, but stem cells also contribute unique combinations of molecules capable of improving tissue repair. This proposal seeks to develop a clinically translatable and controlled approach to deliver potent molecular factors produced by stem cells via engineered biomaterials in order to promote the regeneration of injured tissues in adult mammals.
|Hettiaratchi, Marian H; Miller, Tobias; Temenoff, Johnna S et al. (2014) Heparin microparticle effects on presentation and bioactivity of bone morphogenetic protein-2. Biomaterials 35:7228-38|
|Murphy, William L; McDevitt, Todd C; Engler, Adam J (2014) Materials as stem cell regulators. Nat Mater 13:547-57|
|Goude, Melissa C; McDevitt, Todd C; Temenoff, Johnna S (2014) Chondroitin sulfate microparticles modulate transforming growth factor-?1-induced chondrogenesis of human mesenchymal stem cell spheroids. Cells Tissues Organs 199:117-30|
|Miller, Tobias; Goude, Melissa C; McDevitt, Todd C et al. (2014) Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery. Acta Biomater 10:1705-19|
|Kinney, Melissa A; Hookway, Tracy A; Wang, Yun et al. (2014) Engineering three-dimensional stem cell morphogenesis for the development of tissue models and scalable regenerative therapeutics. Ann Biomed Eng 42:352-67|
|Kinney, Melissa A; McDevitt, Todd C (2013) Emerging strategies for spatiotemporal control of stem cell fate and morphogenesis. Trends Biotechnol 31:78-84|
|Lim, Jeremy J; Temenoff, Johnna S (2013) The effect of desulfation of chondroitin sulfate on interactions with positively charged growth factors and upregulation of cartilaginous markers in encapsulated MSCs. Biomaterials 34:5007-18|